-
1 Comment
ArcticZymes Technologies ASA is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.6.
ArcticZymes Technologies ASA's total revenue rose by 71.2% to $32M since the same quarter in the previous year.
Its net income has increased by 721.4% to $9M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.1% to $12M since the same quarter in the previous year.
Based on the above factors, ArcticZymes Technologies ASA gets an overall score of 5/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | F |
CurrencyCode | EUR |
ISIN | NO0010014632 |
Market Cap | 75M |
---|---|
PE Ratio | 145.5 |
Beta | 1.36 |
Target Price | None |
Dividend Yield | None |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for B4V.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025